Colchicine for Diabetic Nephropathy Trial (CDNT)

The Effect of Colchicine Treatment on the Progression of Proteinuria in Patients With Diabetic Nephropathy.

Forty patients with diabetic nephropathy will be treated with colchicine up to 2 mg, or placebo, for 18 months. A follow up will be performed after 12 additional months. The primary outcome will be a significant reduction or stabilization of proteinuria during the 18 month treatment period.

Study Overview

• Status: Unknown
• Conditions: Diabetic Nephropathies
• Intervention / Treatment: Drug: Colchicine; Drug: Placebo

Detailed Description

Diabetic nephropathy is the leading cause today for end stage renal failure in the western world. Multifactorial intervention in patients may slow the rate of albuminuria and renal injury; however several new drug trials have failed so far to significantly attenuate its progression. Several pathways are identified in the development of diabetic nephropathy, however, in recent years many researchers suspect that inflammatory pathways play central roles in the progression of diabetic neuropathy . There is compelling evidence that diabetes mellitus has an auto-inflammatory component with Nlrp3 inflammasome and interleukin -1 β activation. Colchicine is a relatively safe anti-inflammatory drug used to treat and reverse albuminuria in familial Mediterranean fever nephropathy, an auto-inflammatory disease. Data from one study demonstrated that colchicine diminished proteinuria and inflammation in experimental-diabetic animal models.

Working hypothesis and aims:

To assess whether colchicine reduces proteinuria in diabetic patients with diabetic neuropathy , despite maximal multi-factorial interventions (angiotensin-converting-enzyme inhibitors, tight glycemic and hypertensive control, lifestyle intervention, etc.).

Methods:

Forty patients with stable diabetes, and diabetic neuropathy with proteinuria of 0.5-6g/24 hours, despite standard treatment, will receive colchicine (n=20) or placebo (n=20) for 18 months. Urinary protein and creatinine clearance will be assessed three months before the study initiation, at baseline and every three months thereafter. Blood creatinine, complete blood count, creatine phosphokinase , liver function tests, fasting Glucose Test, HbA1c, and urine protein/creatinine ratio and diabetes mellitus treatment monitoring and follow-up will be performed every three months. Oral colchicine treatment will be initiated at 1mg per day, and increased gradually to 2 mg, if gastrointestinal or musculoskeletal disturbances are absent or tolerated. The participants will be called and evaluated a year after the end of treatment for all parameters mentioned. Statistical analysis will be performed by a statistician.

Expected results:

A significant reduction or stabilization of proteinuria during the 18 month treatment period, or at follow up at one year later.

Importance and Relevance to the call This study may define a new treatment for diabetic nephropathy.

• Study Type: Interventional
• Enrollment (Anticipated): 40
• Phase: Phase 2; Phase 1

Contacts and Locations

• Study Contact: Name: Shaye Kivity, MD; Phone Number: 0526668143; Email: kivitys@gmail.com
• Study Contact Backup: Name: Naomi Friedman, Ms.c; Email: naomi.friedman@sheba.health.gov.il

Study Locations

• Israel
  • Ramat Gan, Israel, 52621
    • Recruiting
    • Sheba Medical Center
    • Contact: Shaye Kivity, MD; Phone Number: 0526668134; Email: kivitys@gmail.com
    • Contact: Naomi Friedman, M.sc; Phone Number: +972544451556; Email: naomi.friedman@sheba.health.gov.il

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Patients with diabetes mellitus , age>18 years old, able to sign an informed consent.
2. Hemoglobin A1c in the range of 6-9%, stable for last year (0.5±)
3. Blood creatinine lower than 2 mg/dL.
4. Blood pressure lower than 140/90 mmHg on stable anti-hypertensive treatment for at least 3 months.
5. Treated with ACE or angiotensin II receptor blocker , unless contraindicated

Exclusion Criteria:

1. Malignancy or significant heart, lung or liver disease.
2. Any GI disease, inflammatory bowel disease , malnutrition ( BMI under 18 )
3. Psychiatric disease
4. Any muscle disease, history of rhabdomyolysis , myopathy or myositis.
5. Any disease causing renal injury/proteinuria apart from diabetes mellitus
6. Any inflammatory or autoimmune disease
7. Any infection during the last month.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Colchicine; 20 patients will receive up to 2 mg of colchicine for 18 months	Drug: Colchicine; up to 2mg of Colchicine daily
Placebo Comparator: Placebo; 20 patients will receive placebo for 18 months	Drug: Placebo; Daily placebo

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Change of urinary protein excretion ( mg/24hrs) from baseline to 18 months.	From baseline to 18 months ( end of trial )

Collaborators and Investigators

• Sponsor: Sheba Medical Center
• Collaborators: D-Cure, Israel
• Investigators: Principal Investigator: Shaye Kivity, MD, Sheba Medical Center

Study record dates

Study Major Dates

• Study Start (Actual): February 22, 2016
• Primary Completion (Anticipated): April 30, 2019
• Study Completion (Anticipated): April 30, 2019

Study Registration Dates

• First Submitted: April 30, 2015
• First Submitted That Met QC Criteria: May 12, 2015
• First Posted (Estimate): May 13, 2015

Study Record Updates

• Last Update Posted (Actual): May 9, 2017
• Last Update Submitted That Met QC Criteria: May 6, 2017
• Last Verified: May 1, 2017

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Urologic Diseases; Endocrine System Diseases; Diabetes Complications; Diabetes Mellitus; Kidney Diseases; Diabetic Nephropathies; Molecular Mechanisms of Pharmacological Action; Antirheumatic Agents; Antineoplastic Agents; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators; Gout Suppressants; Colchicine
• Other Study ID Numbers: SHEBA-2015-1560-SK-CTIL

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES